TYVASO：薬剤分析・市場予測 (～2032年)

当レポートでは、世界の主要6カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国) における肺動脈性肺高血圧症治療薬TYVASOの動向を調査し、当該薬剤の作用機序、規制上のマイルストーン、臨床試験の動向、上市済み薬および開発後期の新興治療薬の概要、市場規模の推移・予測、国別の詳細分析、特許動向、アナリストの見解などをまとめています。

目次

第1章 レポートイントロダクション

第2章 肺動脈性肺高血圧症におけるTYVASO：概要

• 製品の詳細
• 臨床開発
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢：上市済み薬

第4章 競合情勢：開発後期の新興治療薬

第5章 TYVASO市場の評価

• 肺動脈性肺高血圧症におけるTYVASO：市場の展望
• 主要6カ国市場の分析
• 市場分析：国別

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: TYVASO, Clinical Trial Description, 2022
• Table 2: TYVASO : General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5:TYVASO Market Size in the 6MM, in USD million (2019-2032)
• Table 6:TYVASO Market Size in the United States, in USD million (2019-2032)
• Table 7:TYVASO Market Size in Germany, in USD million (2019-2032)
• Table 8:TYVASO Market Size in France, in USD million (2019-2032)
• Table 9:TYVASO Market Size in Italy, in USD million (2019-2032)
• Table 10:TYVASO Market Size in Spain, in USD million (2019-2032)
• Table 11:TYVASO Market Size in the United Kingdom, in USD million (2019-2032)

List of Figures

• Figure 1: Market Size of TYVASO in the 6MM, in USD million (2019-2032)
• Figure 2: Market Size of TYVASO in the United States, in USD million (2019-2032)
• Figure 3: Market Size of TYVASO in Germany, in USD million (2019-2032)
• Figure 4: Market Size of TYVASO in France, in USD million (2019-2032)
• Figure 5: Market Size of TYVASO in Italy, in USD million (2019-2032)
• Figure 6: Market Size of TYVASO in Spain, in USD million (2019-2032)
• Figure 7: Market Size of TYVASO in the United Kingdom, in USD million (2019-2032)

"TYVASO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about TYVASO for Pulmonary Arterial Hypertension in the 6MM. A detailed picture of the TYVASO for Pulmonary Arterial Hypertension in the 6MM, i.e., United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom), for the study period 2019-2032 is provided in this report along with a detailed description of the TYVASO for Pulmonary Arterial Hypertension. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TYVASO market forecast, analysis for Pulmonary Arterial Hypertension in the 6MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Pulmonary Arterial Hypertension.

Drug Summary:

TYVASO DPI is an investigational drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable dry powder inhaler. It is expected to provide a more convenient administration method than traditional nebulized TYVASO therapy.

TYVASO DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin for humans) Inhalation Powder product, which was approved by the FDA in 2014.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the TYVASO description, mechanism of action, dosage and administration, research and development activities in Pulmonary Arterial Hypertension.
• Elaborated details on TYVASO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TYVASO research and development activity in Pulmonary Arterial Hypertension details across the United States, and Europe.
• The report also covers the patents information with expiry timeline around TYVASO.
• The report contains forecasted sales of TYVASO for Pulmonary Arterial Hypertension till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Pulmonary Arterial Hypertension.
• The report also features the SWOT analysis with analyst views for TYVASO in Pulmonary Arterial Hypertension.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TYVASO Analytical Perspective by DelveInsight

• In-depth TYVASO Market Assessment

This report provides a detailed market assessment of TYVASO in Pulmonary Arterial Hypertension in the 6MM, i.e., United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom). This segment of the report provides forecasted sales data from 2022 to 2032.

• TYVASO Clinical Assessment

The report provides the clinical trials information of TYVASO for Pulmonary Arterial Hypertension covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Pulmonary Arterial Hypertension is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TYVASO dominance.
• Other emerging products for Pulmonary Arterial Hypertension are expected to give tough market competition to TYVASO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TYVASO in Pulmonary Arterial Hypertension.
• Our in-depth analysis of the forecasted sales data of TYVASO from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TYVASO in Pulmonary Arterial Hypertension.

Key Questions

• What is the product type, route of administration and mechanism of action of TYVASO?
• What is the clinical trial status of the study related to TYVASO in Pulmonary Arterial Hypertension and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TYVASO development?
• What are the key designations that have been granted to TYVASO for Pulmonary Arterial Hypertension?
• What is the forecasted market scenario of TYVASO for Pulmonary Arterial Hypertension?
• What are the forecasted sales of TYVASO in the 6MM, including the United States, and Europe (Germany, France, Italy, Spain, and the United Kingdom)?
• What are the other emerging products available in Pulmonary Arterial Hypertension and how are they giving competition to TYVASO for Pulmonary Arterial Hypertension?
• Which are the late-stage emerging therapies under development for the treatment of Pulmonary Arterial Hypertension?

Table of Contents

1. Report Introduction

2. TYVASO Overview in Pulmonary Arterial Hypertension

• 2.1 Product Detail
• 2.2 Clinical Development
  • 2.2.1 Safety and Efficacy
• 2.3 Regulatory milestones
• 2.4 Other Development Activities
• 2.5 Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. TYVASO Market Assessment

• 5.1 Market Outlook of TYVASO in Pulmonary Arterial Hypertension
• 5.2 6MM Market Analysis
  • 5.2.1 Market Size of TYVASO in the 6MM for Pulmonary Arterial Hypertension
• 5.3 Country-wise Market Analysis
  • 5.3.1 Market Size of TYVASO in the United States for Pulmonary Arterial Hypertension
  • 5.3.2 Market Size of TYVASO in Germany for Pulmonary Arterial Hypertension
  • 5.3.3 Market Size of TYVASO in France for Pulmonary Arterial Hypertension
  • 5.3.4 Market Size of TYVASO in Italy for Pulmonary Arterial Hypertension
  • 5.3.5 Market Size of TYVASO in Spain for Pulmonary Arterial Hypertension
  • 5.3.6 Market Size of TYVASO in the United Kingdom for Pulmonary Arterial Hypertension

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1 Bibliography
• 8.2 Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Option